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Abstract
Alzheimer’s disease is an age-related progressive neurodegenerative disorder. 
The two major neuropathologic hallmarks of Alzheimer’s disease (AD) are extracel-
lular Amyloid beta (Aβ) plaques and intracellular neurofibrillary tangles (NFTs). 
A number of additional pathogenic mechanisms, possibly overlapping with Aβ 
plaques and NFTs formation, have been described, including inflammation, oxida-
tive damage, iron dysregulation, cholesterol metabolism. To date, only symptomatic 
treatments exist for this disease, all trying to counterbalance the neurotransmitter 
disturbance. To block the progression of the disease they have to interfere with the 
pathogenic steps responsible for the clinical symptoms, including the deposition of 
extracellular amyloid β plaques and intracellular neurofibrillary tangle formation, 
inflammation and stem cell. In this review, we discuss new potential disease-modi-
fying therapies for AD that are currently being studied in phase I–III trials.
Keywords: Alzheimer, secretase modulators, anti-amyloid agents, stem cell
1. Introduction
Alzheimer’s disease (AD) is an age-related progressive neurodegenerative 
disorder characterized by progressive memory loss, cognitive impairment and func-
tional decline. AD is described as a multifactorial disease and several mechanisms 
significant roles in disease pathogenesis. Through an improved understanding of 
the molecular mechanisms underlying pathogenesis of AD, it is possible to develop 
novel, effective therapeutic methods in order to prevent onset and progression of 
AD. A better understanding of the molecular mechanisms underlying pathogenesis 
of AD makes available to a basis for development of novel, effective therapeutic 
strategies to prevent onset and progression of AD.
The formation of intracellular neurofibrillary tangles that are composed of 
hyperphosphorylated tau proteins [1] and accumulation of extracellular amyloid 
plaques are the fundamental neuropathological changes noticed in AD brain. Aβ 
and tau are two key/important proteins, have a main function in the pathogenesis 
of AD. Amyloid cascade hypothesis and tau hypothesis have been based on the 
causative factors in AD pathogenesis. While one of these hypothesis proposes that 
AD starts with the accumulation of Aβ, the other one suggests that AD starts with 
the accumulation of p-tau.
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Amyloid cascade hypothesis: in 1992 Hardy and Higgins constructed the amy-
loid-cascade hypothesis [2]. According to this hypothesis, formation of pathological 
Aβ plaques, neurofibrillary tangles, synaptic loss, neurodegeneration and ulti-
mately dementia in AD are caused by a cascade harming synapses and neurons has 
been triggered by Aβ and its aggregates. Aβ peptides are natural products of brain 
metabolism. AD is associated with the disruption of the balance between produc-
tion and clearance of Aβ. Aβ accumulation in the brain induces oxidative stress and 
inflammatory response thus leads to neurotoxicity which contributes to impairment 
of cognitive functions. Several pathological events like excitotoxicity, synaptic and 
mitochondrial dysfunction, loss of calcium homeostasis, endoplasmic reticulum 
stress, oxidative stress and inflammation may occur as a result of Aβ aggregates. In 
spite of the role of Aβ in AD, only amyloid-cascade hypothesis is not sufficient to 
explain AD pathogenesis, because removal of Aβ did not halt AD pathology [3].
Tau hypothesis: tau is an intracellular protein which is a member of microtubule-
associated proteins family. This protein family promotes microtubule assembly and 
stabilization. Tau has neurotoxic effects when hyperphosphorylated due to loss of 
its normal function. Hyperphosphorylated tau promotes the formation of paired 
helical filaments which would eventually evolve into NFTs, dystrophic neurites, 
and neuropil threads [4]. Abnormal hyperphosphorylation of tau is a component 
of neurofibrillary tangles that is a key player of neurodegeneration and has been 
isolated from AD brain in the 1990s [5].
Although both hypotheses suggest primal roles of Aβ and tau protein in AD 
pathogenesis, increasing evidence suggests that there may be a crosstalk between 
two pathologies. However, the mechanisms linking Aβ toxicity and tau hyperphos-
phorylation have not been exactly clarified yet.
2. Pathogenic mechanisms in Alzheimer’s disease
2.1 Oxidative stress
Oxygen metabolism generates free radicals such as reactive nitrogen spe-
cies (RNS) and reactive oxygen species (ROS) including superoxide anion and 
hydroxyl radical. One of the early changes observed in AD patients is increased 
oxidative damage. It has been shown that the percentages of 8-hydroxydeoxy-
guanosine (8OHdG) and 8-hydroxyguanosine (DNA and RNA oxidation markers), 
4-hydroxynonenal, and F2-isoprostanes (lipid peroxidation markers), protein 
carbonyls and 3-nitrotyrosine (protein oxidation markers), and malondialdehyde 
(MDA), have been increased in AD brains [6]. Although the data is highly limited, 
oxidative stress may also influence hyperphosphorylation and polymerization of tau 
protein. Although oxidative stress has an important role in AD, it is still disputed 
whether it plays a causative role in the disease or secondary to the pathological 
changes observed in AD [7].
2.2 Neuroinflammation
Neuroinflammation is described as a process involving activation of natural 
immunity in the brain. The functions of neuroinflammation can be explained 
as protecting central nervous system from infectious insults, injury or diseases. 
Microglia are has a significant role in neuroinflammation. Transgenic animal models 
of AD have demonstrated that neuroinflammation is enhanced around amyloid 
plaques [8]. According to Bellucci et al. inflammation is the key player in the tauopa-
thies for neurodegeneration [9]. It has been shown that production of enzymes 
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(COX-2) and proinflammatory cytokines (IL-1β) are boosted in tau-positive nerve 
cells in spinal cord and brainstem. Pursuant to these results of the research, neuro-
inflammation might be triggered through NFTs by activating microglia. It is found 
that suppression of neuroinflammation is related to improvements in behavioral and 
cognitive deficits in AD mouse models and is in harmony with decline in hyperphos-
phorylated tau and Aβ plaques in brain. It is efficient to treat with interleukin-1β 
(IL-1β) antibodies or anti-tumor necrosis factor-α (anti-TNF-α) in order to reduce 
the pathology in animal models of AD. It is noted that Aβ secretion and the expres-
sion and activity of β-secretase have been reduced by peroxisome proliferator-
activated receptor-γ [PPAR-γ] agonists and nonsteroidal anti-inflammatory drugs 
[NSAIDs] [10]. It is suggested that suppression of neuroinflammation with NSAIDs 
rescues memory and cognitive decline. While retrospective epidemiological studies 
have proven that prolonged treatment with NSAIDs delays onset of AD when initi-
ated early stage or before disease initiation, its effectiveness has not been demon-
strated in neither mild nor moderate forms of AD [11].
2.3 Metal toxicity
Iron, zinc and copper are important elements for neuronal function. During the 
aging, these metal ions accumulate in the brain, consequently contribute to neu-
rodegeneration. Zinc, copper and iron have been found to be accumulated within 
the core and periphery of senile plaques and these metals have been suggested to be 
involved in Aβ aggregation and oxidative damage. Metal chelation is a therapy based 
on binding and removing to metal ions. This therapy can provide an advantageous 
against oxidative stress in AD. Desferrioxamine and clioquinol are several examples 
of treatment methods with metal chelators. And these methods have caught some 
success in order to alter the progression of AD [12]. Therapeutic approaches focus-
ing on the improvement of metal balance are one of the popular subjects of current 
researches in the field of AD.
2.4 Mitochondrial dysfunction
Mitochondrial dysfunction has a significant function in brain aging and 
AD. Swerdlow and Kan suggested mitochondrial cascade hypothesis for sporadic 
form of AD in 2004 [13]. This hypothesis proposes that mitochondrial dysfunction 
exists early in disease pathogenesis and causes, NFT formation, Aβ deposition and 
synaptic loss, the mitochondria is vulnerable to oxidative stress because of lack 
of DNA repair activity and is the significant source of ROS in the central nervous 
system. Oxidation of mitochondrial DNA presents it vulnerable to somatic muta-
tions which augments mitochondrial dysfunction. Mitochondrial dysfunction has 
been proposed to trigger onset of neuronal degeneration in AD. It is showed that Aβ 
accumulates in mitochondria from AD patients. Tau protein might also be included 
in mitochondrial dysfunction in synapse, indirectly.
2.5 Brain insulin resistance and insulin deficiency
Type 2 diabetes mellitus is a risk factor for AD and these two disorders share 
many common pathological pathways. Impaired glucose metabolism is related to 
rising oxidative stress and accumulated advanced glycation end products. Insulin 
is even produced in brain tissue itself. Insulin receptors are mostly located in the 
cerebral cortex, cerebellum, hypothalamus, hippocampus and olfactory bulb that 
are the cognition pertinent areas of the brain. Brain glucose utilization and insulin 
signaling are impaired in AD. AD is related to a reduction in the levels of insulin in 
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the cerebrospinal fluid (CSF), in the ratio of CSF insulin/plasma insulin, a decline 
in the expression of insulin receptors and a rise in fasting plasma insulin levels. 
Impaired insulin signaling might influence AD pathogenesis via tau hyperphos-
phorylation, acetylcholine signaling and Aβ metabolism. Insulin stimulates the 
expression of choline acetyltransferase, the enzyme responsible for acetylcholine 
synthesis. Therefore, decreased insulin levels, as well as insulin resistance, can 
ultimately contribute to a decrease in acetylcholine in AD brains [14].
2.6 Future therapeutic approaches and management of AD
Alzheimer’s disease [AD] is one of the most challenging threats to the healthcare 
system. The current therapeutic goals are to reduce amyloid levels, prevention of 
amyloid aggregation/toxicity and tau phosphorylation/aggregation. There is also a 
major improvement in understanding the role of cholinesterase [ChE] in the brain 
and the function of ChE inhibitors in AD Academic research has carried out on the 
system of a new generation of acetyl- and butyryl ChE inhibitors and test for AD in 
clinical experiments on human beings. Next to this alternative strategies for treat-
ing or slowing the progression of AD, like vaccination, anti-inflammatory agents, 
cholesterol-lowering agents, antioxidants and hormone therapy, are also studied. 
Although several anti-amyloid β compounds have been examined in clinical trials 
as potentially useful drugs, all of them have failed to show significant benefits 
so far. Tau-targeted drugs have been developed and have entered clinical trials 
recently. The improvements on early diagnostic biochemical markers will be useful 
to increase for better monitoring the course of the disease and to evaluate different 
therapeutic strategies [15].
Academic research of Alzheimer’s disease consists three steps. The first one is to 
select a high-risk population with current evidence and to provide this population 
primary prevention. The goal of this first stage is to be able to manage modifiable 
risk factors. Second is to diagnose patients at the preclinical phase, which starts 
10–20 years before symptoms occur. Researchers aim to find new and improve 
existing neuroimaging techniques, CSF investigations and laboratory and genetic 
studies. The third step is to discover disease-modifying molecules. Researchers are 
aiming to inhibit extracellular amyloid plaque accumulation and to inhibit intracel-
lular tau-based neurofibrillary tangles accumulation [16].
2.6.1 Anti-amyloid agents
One of the main suggested pathophysiological processes is ‘amyloid cascade 
hypothesis’. All autosomal dominant AD genetic forms are the result of mutations of 
amyloid metabolism encoding genes. Also clinical and experimental data indicates 
toxic effects of accumulated amyloid plaques. Amyloid directed therapies can be 
classified in three different classes: amyloid anti-aggregates, secretase modulators 
and immunotherapies [17].
2.6.2 Secretase modulators
To reduce Aβ production, researchers focused on modulate enzymes that break-
down amyloid precursor protein [by stimulating α secretase or inhibiting γ and β 
secretase activity]. While effective α secretase was infrequently, various γ and β 
secretase inhibitors improved. γ secretase plays a decisive role in Aβ generation but 
this enzyme has several cleavage actions including notch receptor signaling so that γ 
secretase inhibitors have significant side effects. β secretase inhibitors also failed to 
show disease-modifying effects but there are still ongoing studies [17].
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2.6.3 Amyloid anti-aggregates
Another strategy is to prevent aggregation of amyloid in non-soluble forms. 
Although new studies report soluble form of Aβ also have toxic effects. It’s known 
that Aβ forms oligomers, fibrils and then deposition of amyloid plaques exist. 
Tramiprosate, colostrinin, clioquinol are some of the studied anti-Aβ aggregation 
agents. There were no effects or minimal effects phase II and III anti-Aβ aggregation 
agents trials on cognition. There are ongoing projects to improve new molecules [18].
2.6.4 Amyloid removal [immunotherapy]
Although it is not proven (exactly) how immunotherapy might attenuate Aβ 
plaques in the brain, some mechanisms have postulated. Therapeutic goal is to 
induce a humoral immune response to fibrillary-Aβ42 or passive administration of 
anti-Aβ antibodies. First studies of active vaccination were halted because of the 
induction of serious side effects. There are ongoing phase I–III studies with active 
and passive immunization (CAD106, bapineuzumab, solanezumab, intravenous 
immunoglobulin) [18].
2.6.5 Tau-based therapies
Tau is a microtubule-associated protein and the MAPT gene encodes tau. 
Assembling microtubules and regulating axonal transport are various functions of 
tau. It is proven that hyperphosphorylated tau causes disruption of mitochondrial 
respiration and axonal transport. It should be emphasized that tau hyperphos-
phorylation is also considered as a pathologic sign of other neurodegenerative 
diseases, including, frontotemporal dementia with parkinsonism (FTD-P), corti-
cobasal degeneration, progressive supranuclear palsy and Pick disease. Mutations 
of tau encoded MAPT1 gene causes FTD-P. Therefore neurodegeneration without 
amyloid deposition can be driven by tau dysfunction. Tau-based therapies are still 
at conceptual stages and include passive immunization against tau, preventing tau 
hyperphosphorylation and anti-aggregates of tau. Methylthioninium chloride and 
lithium are some of the elements with current studies. There are also some experi-
ments ongoing about anti-tau vaccines at AD [19].
3. Treatments that failed in clinical trials
Only four cholinesterase inhibitors (tacrine, donepezil, rivastigmine, galan-
tamine) and an N-methyl-d-aspartate (NMDA) receptor AD antagonist (meman-
tine) are approved for the treatment of AD. These five drugs are all symptomatic 
treatments. No new drugs have been approved for treatment of AD since 2003. 
Disease modifying drugs (DMD) is the real goal in AD treatment. However, success 
rate is extremely low for Alzheimer treatment research. Until today, anti-inflamma-
tory (NSAİD, steroids), antioxidant (selenium, vitamin E), anti-ischemic (statin, 
aspirin), cholinergic (lecithin), nutrients (Omega-3, vitamins B, folic acid), mono-
clonal antibody (bapineuzumab, solanezumab) treatments have failed (Table 1). 
The overall failure rate was 99.6% (0.4% success) in the decade spanning from 2002 
to 2012 [20]. Many explanations have been proposed for the failures of trials of DMD 
for AD, including starting therapies at the late phase of disease, wrong or nonspecific 
treatment targets, incorrect doses, the lack of homogeneity of individuals (genetic, 
ethical, temporal and medical grounds), nonspecific or blunt trial design [21, 22]. 
On the other hand, pathological changes may not correlated with cognitive deficits 
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Agent Proposed mode of action Reason Reference
Ganstigmine Acetylcholinesterase 
inhibitor
Side effects (headache, nausea, 
vomiting, anorexia)
Racchi et al. [23]
Metrifonate Cholinesterase inhibition 
(irreversible)
Side effects (neuromuscular 
dysfunction, respiratory 
failure)
Arrieta et al. 
[24]
Lecithin Major dietary source of 
choline
There is no significant benefit 
of lecithin for Alzheimer’s 
disease or Parkinsonian 
dementia
Higgins and 
Flicker [25]
Ibuprofen Anti-inflammatory, NSAİD No evidence yet exists 
ibuprofen is efficacious in 
Alzheimer’s disease
Tabet and 
Feldman [26]
Rofecoxib Cyclo-oxygenase-2 
inhibition
No significant differences 
between treatments were found 
for the ADAS-cog score
Reines et al. [27]
Aspirin, steroid Anti-inflammatory No significant improvement in 
cognitive decline for aspirin and 
steroid
Jaturapatporn 
et al. [28]
Latrepirdine Antihistamine drug There is no effect of latrepirdine 
on cognition and function in 
mild-to-moderate AD patients
Chau et al. [29]
Selegiline Monamine oxidase 
inhibition
The evidence of benefit using 
standardised global cognitive 
scales was extremely limited. 
There is not yet enough 
evidence to recommend its use 
in practice
Birks and Flicker 
[30]
Pravastatin Lowers plasma cholesterol 
and lipoprotein
Pravastatin had no significant 
effect on cognitive function or 
disability
Shepherd [31]
Simvastatin, 
pravastatin
Lowers plasma cholesterol 
and lipoprotein
There is no evidence that statins 
prevent cognitive decline or 
dementia
McGuinness 
et al. [32]
Omega-3 
polyunsaturated 
fatty acids
Essential dietary nutrient There is not convincing 
evidence for the efficacy of 
omega-3 PUFA supplements 
in the treatment of mild to 
moderate AD
Burckhardt et al. 
[33]
Vitamin E, 
selenium
Antioxidant supplement Antioxidant supplements did 
not prevent dementia
Kryscio et al. 
[34]
Vitamin E Vitamin E, selenium There is no evidence that 
vitamin E prevents dementia, 
or that it improves cognitive 
function in people with MCI 
or AD
Farina et al. [35]
Vitamins B Methionine-synthase 
mediated conversion 
of homocysteine to 
methionine, antioxidant, 
nerve growth and repair
There is no adequate evidence 
of an effect of vitamins B on 
general cognitive function, 
executive function
Li et al. [36]
Acetyl-l-
carnitine
Activity at cholinergic 
neurons, membrane 
stabilization and enhancing 
mitochondrial function
There is no evidence of benefit 
of improvement in cognition or 
functional ability
Hudson [37]
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in AD, measuring cognitive abilities is a reductionist approach as the disease is too 
complex and transgenic animal models are not capable of mimicking the various 
pathophysiological mechanisms in humans. Several new chemical entities claim-
ing to have potential benefits in AD have been developed by researchers all over 
the globe. However, the evolution of a definite disease modifying therapy for AD is 
constantly under the threat of chasing the wrong pathology [22].
4. Ongoing clinical trials for Alzheimer’s disease
Alzheimer’s disease (AD) is a neurodegenerative disorder resulting from progres-
sive pathological changes characterized by protein deposits in the form of amyloid 
plaques (APs) and neurofibrillary tangles (NFTs), which cause synaptic and 
neuronal loss. According to generally accepted hypothesis AD starts with abnormal 
processing of amyloid precursor protein (APP) [2]. Excess production or reduced 
clearance of β-amyloid peptide monomers, which is produced by the amyloidogenic 
cleavage of the membrane-spanning protein APP are the two main mechanisms of 
this abnormal deposition process, which causes aggregation of β-amyloid (Aβ) fibrils 
in extracellular APs. Second core pathophysiological mechanism of the disease is the 
intraneuronal deposition of hyperphosphorylated tau (pT) within NFTs [5].
Synaptic dysfunction, mitochondrial and oxidative changes, neuroinflamma-
tion, gliosis, and finally apoptosis and neuronal loss are known neurodegenerative 
consequences of AD, which are reflected in the macroscopical level as the regional 
cortical atrophy starting from limbic regions of the brain and then traveling trans 
synaptically to paralimbic, heteromodal and finally to unimodal association 
cortices. These changes and dysfunctions of the neurotransmitter systems such 
as acetylcholine, serotonin, glutamate, noradrenaline, dopamine cause clinical 
manifestations.
All these pathological changes are the targets of ongoing clinical trials for the 
treatment of AD. The term “disease-modifying strategies in AD” primarily connotes 
Agent Proposed mode of action Reason Reference
Piracetam Multiple complex 
mechanisms
The evidence does not 
support the use of piracetam 
in the treatment of people 
with dementia or cognitive 
impairment
Flicker and 
Evans [38]
Semagacestat γ-Secretase inhibition Serious adverse events 
(weight loss, skin cancers and 
infections), worsening of 
cognition and functioning
Doody et al. [39]
Tarenflurbil(R-
flurbiprofen)
γ-Secretase inhibition No effect on cognitive decline or 
the loss of daily living activities 
in mild AD
Green et al. [40]
Bapineuzumab Humanized, N-terminal 
specific anti-Aβ monoclonal 
antibody
No significant improvement in 
cognition, serious side effects, 
vasogenic edema
Abushouk et al. 
[41]
Solanezumab Humanized monoclonal 
IgG1 antibody directed 
against the mid-domain of 
the Aβ peptide
No significant improvement in 
cognition
Honig et al. [42]
Table 1. 
The anti-AD drug candidates for which the clinical trials have been failed or suspended.
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treatment strategies aiming at the prevention of and/or clearance of pathological Aβ 
and tau. Neurotransmitter-based strategies and others, such as combatting against 
oxidative stress or neuroinflammation are generally classified as “symptomatic 
treatments”. In this section, current disease-modifying and symptomatic treatment 
strategies will be reviewed.
4.1 Amyloid-focused ongoing clinical trials
According to the amyloid cascade hypothesis, AD begins with the accumula-
tion of Aβ, years before its clinical onset. APP is a transmembrane protein whose 
physiological function is not completely understood. In a healthy brain, APP is 
metabolized by three proteolytic enzymes, namely α, β and γ secretases [43]. 
Proximally, γ-secretase cleaves the protein in its membrane-spanning domain 
solely by itself, forming an intracellular carboxy-terminal fragment (CTF), which 
is probably pro-plastic by translocating into the neuronal nucleus and playing a 
role in pro-plastic signaling. However distally, APP is cleaved alternatively, either 
by α-secretase or by β-secretase (BACE) on its two different sites in the extracel-
lular domain close to the amino terminal of APP. The former cleavage is non-
amyloidogenic since it produces an inert peptide called p3 in the mid-segment 
and another one, which is called sAPPα containing the N-terminus and probably 
having some neurotrophic functions. However, the latter cleavage is amyloido-
genic, since it produces the anti-plastic and deposition-prone Aβ fragment in 
the mid-segment and sAPPβ in the N-terminus. The resulting Aβ will either be 
cleared by lysosomal-proteasomal mechanisms or will oligomerize and start to 
induce its pathophysiological functions. Now it is known that soluble oligomers of 
Aβ are more toxic than its more downstream moieties that are insoluble protofi-
brils and fibrils [44, 45].
Therefore, current studies aim to agonize α-secretase activity (ADAM10 activa-
tors), inhibit β-secretase (BACE inhibitors), and inhibit or modulate γ-secretase 
(GSIs and GSMs). Also enhancing clearance of Aβ with active or passive immuno-
therapies or prevention of aggregation of APs are the treatment focuses of ongo-
ing trials. Monoclonal antibodies bind different epitopes which are N-terminal, 
C-terminal or mid-domain of Aβ and different conformations of Aβ which are 
monomer, oligomer and fibril [46].
4.1.1 Reducing Aβ production
Two secretases, namely α and γ are seemingly no longer the focus of drug 
development efforts for AD, as a result of many failures in clinical trials and 
concerns that their interaction with other substrates may trigger diseases like 
cancer. Specific ADAM10 activators that will act only in the brain thus preventing 
its potential role in breast cancer is yet to be developed [47] In a recent review it 
was stated that “the future of γ-secretase inhibition as an AD treatment strategy 
may depend on the development of GSMs, which aim to cause a shift from Aβ1-42 
species toward the shorter and less pathogenic forms of Aβ, while also sparing 
Notch” [48].
β-Secretase is an aspartic acid protease belongs to the pepsin family. β-Site 
APP cleaving enzyme 1 (BACE1) plays role in Aβ production. BACE1 inhibition 
strategies do not share the same concerns for interfering with the other secretases. 
Therefore BACE1 inhibition is one of the strategies to interfere with amyloid 
cascade. There are ongoing trials with E 2609 (NCT03036280, NCT02956486), 
CNP520 (NCT02565511, NCT03131453) and JNJ-54861911 (NCT02569398, 
NCT01760005) [49].
9Future Treatment of Alzheimer Disease
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4.1.2 Aβ clearance
The first experience of active vaccine trial was with AN1792 and ended occur-
rence of T-cell mediated meningoencephalitis [50]. Now the only ongoing active 
vaccine trial is CAD-106 that generates anti-Aβ antibodies to N-terminus [51, 52].
Crenezumab is a humanized IgG4 monoclonal antibody (mAb) that binds 
the mid-domain of the Aβ peptide (residues 13–24) and binds multiple confor-
mations of Aβ (monomers, oligomers, fibrils) [53, 54]. Patients with mild to 
moderate Alzheimer Disease and also Preclinical Presenilin1 (PSEN1) E280A 
Mutation Carriers are involved in ongoing trials of Crenezumab (NCT03491150, 
NCT03114657, NCT02353598, NCT01998841, NCT02670083).
Gantenerumab is a first fully human IgG1 mAb binds an N-terminal [3–12] 
and central [18–27] amino acids of the Aβ peptide. It binds monomers weaker 
than oligomers and fibrils [46]. Gantenerumab is being evaluated in phase 2 and 
3 trials in individuals with prodromal and early AD and individuals at risk for 
and with early-stage autosomal-dominant AD (NCT02051608, NCT03444870, 
NCT03443973, NCT01224106, NCT01760005) [46, 55, 56].
Aducanumab is a fully human IgG1 mAb binds the N-terminus (residues 3–6) of 
Aβ peptide. It recognizes oligomers and fibrils but it does not react to the monomers 
[18]. Ongoing Aducanumab trials involve prodromal, early and mild AD patients 
(NCT03639987, NCT02484547, NCT02477800, NCT01677572) [46, 57].
Solanezumab is a humanized IgG1 mAb, binds the mid-domain of Aβ (residues 
16–26). It specifically recognizes monomers [58]. There are two ongoing prevention 
trials with solanezumab (NCT01760005, NCT02008357).
4.1.3 Other anti-amyloidogenic compounds
In addition to abovementioned strategies, there are some other anti-amyloido-
genic compounds with diverse mechanisms. ALZT-OP1 prevents Aβ aggrega-
tion and neuroinflammation and is being evaluated in phase III clinical trial 
(NCT02547818) [59]. Posiphen is another anti-amyloidogenic drug that currently in 
phase I/II clinical trial (NCT02925650) [60].
Update of selected anti-Alzheimer’s disease drugs in clinical trials including 
anti-amyloid strategies are summarized in Table 2.
4.2 Tau-focused ongoing clinical trials
Tau is a microtubule-associated protein (MAP) in neurons which regulates the 
axonal transport [63]. Although tau pathology proved to be more correlated with 
clinical symptoms than amyloid mechanisms, tau-based therapeutic strategies are 
relatively new. Beta-folded oligomers of abnormal phosphorylation of tau are the 
main component of NFTs. Post-translational modifications such as phosphoryla-
tion, acetylation and truncation play a major role in tau function [64]. Modulating 
tau phosphorylation, targeting other tau post-translational modifications, micro-
tubule stabilizers, tau aggregation inhibitors, anti-tau immunotherapy are the 
mechanisms targeted by clinical trials. Current clinical trials focusing on tau are 
summarized in Table 3.
4.2.1 Targeting tau-post-translational modifications
Salsalate is a nonsteroidal anti-inflammatory drug that has been shown to inhibit 
acetyltransferase p300-induced tau acetylation in frontotemporal dementia (FTD) 
mouse model [75]. There is a phase I clinical trial in patients with prodromal to mild 
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Target Drug name Study title Therapy type Trial 
status
Company Clinical trial 
identifier
BACE inhibitor E2609 
Elenbecestat [49]
A 24 Month Study to Evaluate the Efficacy and Safety 
of E2609 in Subjects with Early Alzheimer’s Disease_ 
(MissionAD2)
Small molecule Phase III Biogen, Eisai Co., Ltd. NCT03036280
A 24-Month Study to Evaluate the Efficacy and 
Safety of E2609 in Subjects with Early Alzheimer’s 
Disease_ (MissionAD2)
Small molecule Phase III Biogen, Eisai Co., Ltd. NCT02956486
CNP520 [49] A Study of CAD106 and CNP520 Versus Placebo 
in Participants at Risk for the Onset of Clinical 
Symptoms of Alzheimer’s Disease
Small molecule Phase II/III Amgen, Inc., Novartis 
Pharmaceuticals 
Corporation
NCT02565511
A Study of CNP520 Versus Placebo in Participants 
at Risk for the Onset of Clinical Symptoms of 
Alzheimer's Disease
Small molecule Phase II/III Amgen, Inc., Novartis 
Pharmaceuticals 
Corporation
NCT03131453
JNJ-54861911 [49] An Efficacy and Safety Study of Atabecestat in 
Participants Who Are Asymptomatic at Risk for 
Developing Alzheimer’s Dementia (EARLY)
Small molecule Phase II/III Janssen, Shionogi Pharma NCT02569398
Dominantly Inherited Alzheimer Network Trial: 
An Opportunity to Prevent Dementia. A Study 
of Potential Disease Modifying Treatments in 
Individuals at Risk for or With a Type of Early Onset 
Alzheimer’s Disease Caused by a Genetic Mutation.
Small molecule Phase II/III Janssen, Shionogi Pharma NCT01760005
Aβ clearance CAD106 [49, 61] A Study of CAD106 and CNP520 Versus Placebo 
in Participants at Risk for the Onset of Clinical 
Symptoms of Alzheimer's Disease
Active 
immunotherapy
Phase II/III Novartis Pharmaceuticals 
Corporation
NCT02565511
Crenezumab An Open-Label Crenezumab Study in Patients with 
Alzheimer’s Disease
Passive 
immunotherapy
Phase III Hoffmann-La Roche NCT03491150
A Study of Crenezumab Versus Placebo to Evaluate 
the Efficacy and Safety in Participants with 
Prodromal to Mild Alzheimer’s Disease (CREAD 2)
Phase III Hoffmann-La Roche NCT03114657
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Target Drug name Study title Therapy type Trial 
status
Company Clinical trial 
identifier
A Study of Crenezumab Versus Placebo in Preclinical 
Presenilin1 (PSEN1) E280A Mutation Carriers to 
Evaluate Efficacy and Safety in the Treatment of 
Autosomal-Dominant Alzheimer’s Disease, Including 
a Placebo-Treated Non-Carrier Cohort [27]
Phase II • Genentech, Inc.
• Banner Alzheimer’s 
Institute
• National Institute on 
Aging (NIA)
NCT01998841
CREAD Study: A Study of Crenezumab Versus 
Placebo to Evaluate the Efficacy and Safety in 
Participants with Prodromal to Mild Alzheimer’s 
Disease [20]
Phase III AC Immune SA, 
Genentech, Hoffmann-La 
Roche
NCT02670083
Gantenerumab A Study of Gantenerumab in Participants with Mild 
Alzheimer Disease
Passive 
immunotherapy
Phase III Hoffmann-La Roche NCT02051608
A Study of Gantenerumab in Participants with 
Prodromal Alzheimer’s Disease [56]
Phase III Hoffmann-La Roche NCT01224106
Dominantly Inherited Alzheimer Network Trial: 
An Opportunity to Prevent Dementia. A Study 
of Potential Disease Modifying Treatments in 
Individuals at Risk for or With a Type of Early Onset 
Alzheimer’s Disease Caused by a Genetic Mutation. 
(DIAN-TU) [55]
Phase II
Phase III
• Washington University 
School of Medicine, 
Eli Lilly and Company, 
Hoffmann-La Roche 
(and 5 more)
NCT01760005
Aducanumab A Study of Aducanumab in Participants with Mild 
Cognitive Impairment Due to Alzheimer’s Disease or 
With Mild Alzheimer’s Disease Dementia to Evaluate 
the Safety of Continued Dosing in Participants 
with Asymptomatic Amyloid-Related Imaging 
Abnormalities
Passive 
immunotherapy 
(against aggregated 
Aβ)
Phase II Biogen NCT03639987
221AD302 Phase 3 Study of Aducanumab (BIIB037) 
in Early Alzheimer’s Disease (EMERGE) [46]
Phase III Biogen NCT02484547
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Target Drug name Study title Therapy type Trial 
status
Company Clinical trial 
identifier
21AD301 Phase 3 Study of Aducanumab (BIIB037) in 
Early Alzheimer’s Disease (ENGAGE) [46]
Phase III Biogen NCT02477800
Multiple Dose Study of Aducanumab (BIIB037) 
(Recombinant, Fully Human Anti-Aβ IgG1 mAb) 
in Participants with Prodromal or Mild Alzheimer’s 
Disease (PRIME) [57]
Phase I Biogen NCT01677572
Solanezumab Dominantly Inherited Alzheimer Network Trial: 
An Opportunity to Prevent Dementia. A Study 
of Potential Disease Modifying Treatments in 
Individuals at Risk for or With a Type of Early Onset 
Alzheimer’s Disease Caused by a Genetic Mutation. 
(DIAN-TU) [55]
Passive 
immunotherapy 
(against Aβ3–12 and 
Aβ18–27)
Phase II
Phase III
• Washington University 
School of Medicine
• Eli Lilly and Company
• Hoffmann-La Roche 
(and 5 more)
NCT01760005
Clinical Trial of Solanezumab for Older Individuals 
Who May be at Risk for Memory Loss [62]
Phase III • Eli Lilly and Company
• Alzheimer’s Therapeutic 
Research Institute
NCT02008357
Other Anti-
amyloidogenic 
Compounds
ALZT-OP1 [59] Safety and Efficacy Study of ALZT-OP1 in Subjects 
with Evidence of Early Alzheimer’s Disease 
(COGNITE)
Phase III AZTherapies, Inc. NCT02547818
Posiphen® [60] Safety, Tolerability, PK and PD of Posiphen® 
in Subjects with Early Alzheimer’s Disease 
(DISCOVER)
Phase I
Phase II
• QR Pharma Inc.
• Alzheimer’s Disease 
Cooperative Study 
(ADCS)
NCT02925650
Table 2. 
Update of selected anti-Alzheimer’s disease drugs in clinical trials including anti-amyloid strategies.
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Company/sponsor Clinical trial 
identifier
Lisin acetylation 
inhibitor
Salsalate [65] Salsalate in Patients Mild to Moderate Alzheimer’s Disease Small molecule Phase I Adam Boxer NCT03277573
c-Abl inhibitor Nilotinib [66] Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to 
Moderate Alzheimer’s Disease
c-Abl inhibitor Phase II Georgetown University NCT02947893
Microtubule 
stabilizers
TPI-287 A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and 
Preliminary Efficacy Study of TPI-287 in Alzheimer’s Disease
Small molecule Phase I Cortice Biosciences NCT01966666
Tau aggregation 
inhibitors
TRX-0237 [67, 68] Safety and Efficacy of TRx0237 in Subjects with Early Alzheimer's Disease Small molecule Phase II-III • TauRx Therapeutics Ltd NCT03446001
Nicotinamide Nicotinamide as an Early Alzheimer’s Disease Treatment (NEAT) Lysosomal 
acidification
Phase II • University of California, 
Irvine
NCT03061474
Anti-Tau 
immunoteraphies
AADvac-1 [67] 24 Months Safety and Efficacy Study of AADvac1 in Patients with Mild 
Alzheimer's Disease
Active 
immunotherapy
Phase II Axon Neuroscience SE NCT02579252
ACI-35 [19] A study comparing the safety and effects of a new compound, ACI-35 with 
placebo in patients with mild to moderate Alzheimer’s disease
Active 
immunotherapy
Phase I AC Immune SA, Janssen ISRCTN13033912
IvIg [69–71] Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive 
Impairment
Active 
immunotherapy
Phase II • Sutter Health NCT01300728
A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's disease Active 
immunotherapy
Phase II
Phase III
Instituto Grifols, S.A./
Grifols Biologicals Inc.
NCT01561053
ABBV-8E12 
[72, 73]
A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with 
Early Alzheimer’s Disease
Passive 
Immunotherapy
Phase II AbbVie NCT02880956
An Extension Study of ABBV-8E12 in Early Alzheimer’s Disease Passive 
Immunotheraphy
Phase II AbbVie NCT03712787
RO 7105705 [74] A Study to Evaluate the Efficacy and Safety of RO7105705 in Patients with 
Prodromal to Mild Alzheimer’s Disease
Passive 
Immunotheraphy
Phase II Genentech, Inc NCT03289143
Table 3. 
Current clinical trials focusing on tau.
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AD (NCT03277573). Nilotinib is a c-Abl tyrosine kinase inhibitor used in patients 
with leukemia [76]. It is thought to clean tau by inducing autophagy. It is being evalu-
ated in a phase II clinical trial in patients with mild to moderate AD (NCT02947893).
4.2.2 Microtubule stabilizers
TPI-287 is a small molecule that stabilizes microtubules. It is tested in a phase I 
clinical trial in AD patients [77].
4.2.3 Tau aggregation inhibitors
LMT-X or named as TRx0237 is a second generation formulation of methylene 
blue that targets tau accumulation [77]. There is a phase II/III clinical trial in 
patients with early AD (NCT03446001) [67, 68]. Nicotinamide is the precursor of 
coenzyme Nicotinamide adenine dinucleotide prevents phosphorylation of tau in 
mice. A phase II study in mild-to-moderate Alzheimer’s disease is currently ongoing 
(NCT03061474).
4.2.4 Active immunotherapy
There are three active immunotherapy agents being evaluated in ongoing trials. 
AADvac-1 contains synthetic tau peptide spanning residues 294–305 derived from a 
naturally occurring truncated and misfolded tau protein coupled to keyhole limpet 
hemocyanin and aluminum hydroxide as adjuvant [77]. A phase II clinical trial 
in subjects with mild AD is ongoing (NCT02579252) [78]. ACI-35 is a synthetic 
peptide spanning the human protein tau sequence 393–408, phosphorylated at 
S396 and S404 [72]. A phase I clinical trial in subjects with mild to moderate AD is 
ongoing (ISRCTN13033912) [19]. Intravenous immunoglobulin (IVIg) is a human 
plasma-derived product consisting of polyclonal serum IgG used as anti-inflamma-
tory and immunomodulatory therapy for various neurological diseases [73]. There 
are phase II and III studies in subjects with mild cognitive impairment and AD 
(NCT01300728, NCT01561053) [69, 70].
4.2.5 Passive immunotherapy
ABBV-8E12 is a humanized anti-tau monoclonal antibody. There are two studies 
with ABBV-8E12 in patients with early AD (NCT02880956, NCT03712787) [72, 73]. 
Another passive immunotherapy agent R07105705 is an anti-tau antibody [39]. It is 
being evaluated in patients with prodromal to mild AD (NCT03289143) [74].
4.3 Other ongoing clinical trials
Riluzole, a sodium channel blocker, is used as a disease-modifying drug for amyo-
trophic lateral sclerosis [79]. It lowers extracellular glutamate levels, inhibits presyn-
aptic glutamate release and induces glutamate transporter activity. Riluzole is being 
evaluated in a Phase II clinical trial in patients with mild AD (NCT01703117) [79–82].
LMA11A-31 is a small molecule prevents synaptic dysfunction, spine loss, 
neurite degeneration, microglial activation, and cognitive deficits in animal 
models [83, 84]. A phase I/II trial with mild to moderate AD patients is ongoing 
(NCT03069014) [85]. AD is thought to be linked with viral infections [86, 87]. 
Therefore a phase II trial is ongoing in mild AD patients who test positive for serum 
antibodies for herpes simplex virus 1 or 2, with valacyclovir (NCT03282916). 
Lifestyle interventions, management of metabolic and cardiovascular risk factors, 
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Glutaminergic Riluzole [79–82] Riluzole in Mild Alzheimer’s Disease Small 
molecule
Phase II Sanofi NCT01703117
Neurotrophins and Their Receptor-
based Therapies
LM11A-31-BHS [85] Study of LM11A-31-BHS in Mild–
moderate AD Patients
Phase I
Phase II
• PharmatrophiX Inc.
• National Institute on 
Aging (NIA)
NCT03069014
Therapies Targeted at 
Neuroinflammation and Oxidative 
Stress
Valacyclovir [85] Anti-viral Therapy in Alzheimer’s 
Disease
Phase II New York State 
Psychiatric Institute
National Institutes of 
Health (NIH)
National Institute on 
Aging (NIA)
NCT03282916
Therapies and Interventions for AD 
Prevention
Insulin (Humulin R® 
U-100) [85]
The Study of Nasal Insulin in the Fight 
Against Forgetfulness (SNIFF)
Phase II
Phase III
NCT01767909
Table 4. 
Other strategies of Alzheimer’s disease treatment.
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exercise and diet are the focuses for primary prevention of AD (NCT01767909, 
NCT03249688) [88–92].
Deep brain stimulation is a novel therapeutic strategy for AD. One trial is 
ongoing in patients with mild AD (NCT03622905). Other strategies of Alzheimer’s 
disease treatment are summarized in Table 4.
5. Gene and stem cell therapy in Alzheimer disease
5.1 Genetics of Alzheimer’s disease
Both age and family history are important risk factors for AD. The risk of devel-
oping AD increases for one who has a first-degree relative with AD when compared 
to the general population. AD can be grouped into two subtypes with respect to age 
of onset. Most of the AD cases (>95%) are late-onset AD (sporadic/LOAD) (above 
age 65) that is considered to be multifactorial [93]. Many susceptibility genes for 
LOAD have been defined thanks to genome-wide association studies (GWAS) and 
several other sequencing analyzes. For instance, one of the well-studied genetic risk 
factors for LOAD is an alteration in Apolipoprotein E (APOE) coded by the gene 
localized to 19q13 [94]. APOE is a multifunctional protein which serves a number 
of functions in neuronal activities. In brain tissue, there are three main isoforms 
that are diversified by each other by different one amino acid, which are APOEε2 
(Cys112, Cys158), APOEε3 (Cys112, Arg158) and APOEε4 (Arg112, Arg158). The 
differences between these three APOE isoforms have a significant impact on the 
structure and function of APOE at molecular and cellular levels. Therefore, those 
are thought as associated with neuropathological conditions [95].
Early onset AD (Familial/EOAD) represent <5% of all cases of AD. APP 
(Amyloid beta (A4) precursor protein), PSEN1 (Presenilin 1), and PSEN2 
(Presenilin 2) genes mutations are exclusively considered as a basis for EOAD 
in most cases [94]. APP, a transmembrane protein in neuron cells, is cleaved by 
β-secretase and γ-secretase, respectively, to produce β-amyloids (Aβ) and some 
other side products [96]. Since neurotoxic consequences of altered Aβ ratios like 
neurodegeneration resulting from aberrant synaptic function take place in brain, 
APP mutations have continuously been investigated. Yet, only approximately 15% 
of EOAD could be enlightened by dominant APP gene mutations [97].
Another protein that is strictly associated with the progression of AD is PSEN1 
as it is the principal component of γ-secretase complex. Since neurotoxic fragments 
are formed by proteolytic function of γ-secretase on APP, PSEN1 gene mutations 
give rise to abnormal activity of the proteolytic enzyme leading to abnormal or 
longer Aβ fragments and, therefore this contributes to development of EOAD [95]. 
More than 180 autosomal dominant PSEN1 mutations associated with AD have been 
reported, which makes PSEN1 significantly important protein in the occurrence 
of EOAD [98]. Disease-causing PSEN1 gene mutations, showing complete pen-
etrance, accounts for majority of EOAD (approximately 80%) and these mutations 
are defined as the most common cause of the disease [99]. Lastly, the gene PSEN2 
is also coding for one subunit of γ-secretase, the aspartyl protease generates Aβ. 
Missense mutations are reported in PSEN2, which are rarely genetic basis of EOAD 
[100]. In total, as mentioned in Zou’s review article in 2013, majority of the disease-
causing mutations identified for the EOAD have been reported in PSEN1 gene 
(approximately 78%), followed by APP mutations (17%) then with rare PSEN2 
gene mutations (approximately 5%) [94].
Technological advances in sequencing methods over the past decade allow 
researchers to investigate AD thoroughly, especially genetic fundamentals of the 
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disease. Since high-throughput sequencing provides a large number of polymor-
phisms in numerous subjects, new several genes associated with AD risk have been 
emerged and reported [96]. Accordingly, genome-wide association studies (GWAS) 
about AD increased, which consequently suggests new gene therapy strategies.
5.2 Gene therapy for AD
Discovering risk loci by GWAS studies may help to enlighten the biological 
mechanisms underlying AD because the reported genes might have been target for 
medicines, thereby this issue promises further investigation in order to improve 
gene therapy strategies and thus precision medicine concept for AD [101].
Over time, gene delivery of nerve growth factor (NGF), brain-derived neuro-
trophic factor (BDNF), APOE, ECE (endothelin-converting enzyme) have been 
investigated in several animal models of AD. Endothelin-converting enzyme (ECE) 
is protease involved in the degradation of Aβ peptides. Intracranial administration 
of five recombinant adeno-associated viral vector (rAAV) containing the ECE-1 
synthetic gene showed reduced Aβ in the anterior cortex and hippocampus in 
APP-PS1 transgenic mice. Use of AAV vector encoding anti-Aβ Ab in Tg2576 mice 
results in a significant decrease in Aβ level in the brain of subjects. These results 
support its use for the prevention and treatment of AD [102].
The first clinical trial using Adeno-Associated Virus delivery of NGF has been 
accomplished and the results indicate amelioration of AD pathogenesis. Clinical tri-
als were conducted using CERE-110 that is an AAV2/2 vector containing full length 
NGF transgene for the treatment of AD patients. These trials confirmed that AAV2-
NGF delivery was well tolerated with a high level of safety and no systemic toxicity 
but did not affect clinical outcomes or selected AD biomarkers (NCT00087789, 
NCT00876863) [103].
5.3 Stem cell treatment for AD
Stem cells (SCs) are continuously capable of self-renewing and differentiat-
ing into specialized cells. Accordingly, SC therapy is surely becoming a promising 
strategy in the treatment of neurodegenerative diseases including AD owing to 
the capacity of SCs to migrate and reach areas of the brain. SCs are classified into 
four groups; embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), 
mesenchymal stem cell, and neural stem cells [104].
5.3.1 Embryonic stem cells (ESCs)
ESCs, called as pluripotent, are derived from the inner cell mass of blastocyst 
because they have the ability to develop cell types from the ectoderm, mesoderm, 
and endoderm germ layers [105]. ESCs may an excellent cell replacement therapy 
approaches for transplantation in AD [104]. In vitro studies have been successful to 
differentiate ESCs into specific neuronal cell types like dopaminergic neurons and 
these studies show that the role of ESCs and their derivatives reduce AD pathology 
in rodent models [106, 107].
Several studies reveal that ESC-derived NSCs can be safely transplanted 
without tumorigenesis despite the fact that undifferentiated ESCs have risks of 
tumor formation, transplantation rejection and immune responses [106, 108, 109]. 
Experiments conducted on human ESCs have been able to generate dopaminergic 
neurons, spinal motor neurons and astroglial cells [110]. Some studies demon-
strated use of retinoic acid (RA) induce direct differentiation of human ESCs into 
basal forebrain cholinergic neurons (BFCNs). Tang et al. showed that ESC-derived 
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NPC transplantation into an Aβ-injured rat model improves memory impairment 
compared to sham controls [106].
5.3.2 Induced pluripotent stem cells (IPSCs)
Induced pluripotent stem cells could be generated from adult cells by the over-
expression of key transcription factors (OCT4, SOX2, KLF4, LIN28, and NANOG) 
[111, 112]. iPSCs are in general similar to embryonic stem cells (ESCs) in morphol-
ogy, gene expression profile and potential of differentiation [113].
Human iPSCs derived from AD patients’ somatic cells can provide a new per-
spective to develop new strategies for disease modeling. Yagi et al. showed that 
fAD-iPSC-derived differentiated neurons have increased amyloid β42 secretion, 
responds to γ-secretase inhibitors and modulators, indicating the potential for 
identification and validation of candidate drugs [114]. Takamatsu et al. used iPSCs 
to derive macrophage-like myeloid lineage cells that could express neprilysin which 
is a protease with Aβ-degrading activity [115].
Recent studies have shown reprogramming structural chromosomal abnormali-
ties and aberrant DNA methylation patterns in hiPSCs [116]. iPSCs can be edited 
by gene editing technologies like recombinant homologous, transcription activator-
like effector nucleases (TALENs), clustered regularly interspaced short palindromic 
repeats (CRISPR-cas9) and can function as more suitable for cell transplantation.
5.3.3 Mesenchymal stem cells (MSCs)
Mesenchymal stem cells (MSCs) are adult multipotent progenitors and can be 
obtained from various adult tissues including bone marrow, peripheral blood, umbilical 
cord, adipose tissue, amniotic fluid. MSCs are most favored cell types in the treatment 
of AD due to their accessibility, relative ease of handling, secretion of a wide range of 
cytokines, easily transplanted intravenously into patients, and lack of ethical issues.
Most important features of ESCs is a wide range of differentiation potentials 
including neuronal cells [110]. Park et al. reported that transplanted human adipose 
tissue derived mesenchymal stem cells (ADMSCs) differentiate into neural cells 
in the brain and these cells can restore cognitive functions of mice by increasing 
acetylcholine synthesis, brain-derived neurotrophic factor (BDNF), nerve growth 
factor (NGF) and restoring neuronal integrity [117]. In addition, MSC transplan-
tation has been shown to inhibit Aβ and tau-related cell death, and to reduce Aβ 
residues and plaque formation by modulating neuroinflammation [118, 119]. It 
has been reported that bone marrow-derived mesenchymal stem cells provide a 
reduction in Aβ deposits and facilitate changes in key proteins required for synaptic 
transmissions such as dynamin 1 and synapsin 1 [120].
5.3.4 Neural stem cells (NSCs)
Transplantation of growth factor-secreting NSC was reported to increase neuro-
genesis and cognitive function in a rodent AD model [121]. And the overexpression 
of NSC derived cholinergic neurons restored cognitive performance and synaptic 
integrity in a rodent model [122].
6. Conclusion
Alzheimer’s disease is a progressive neurodegenerative disease that affects the 
central nervous system. Many complex pathological and genetic features have been 
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described in the disease. Aβ aggregation, tau aggregation, metal dyshomeostasis, 
oxidative stress, cholinergic dysfunction, inflammation and downregulation of 
autophagy based on pathophysiological changes occur during the onset and pro-
gression of AD have been proposed. There is no effective treatment currently, how-
ever, at present, current drug treatments of AD, such as cholinesterase inhibitors or 
NMDA antagonists, mainly help to manage symptoms hereby obviating the need 
for new approaches to deal with AD underlying mechanisms. Ongoing advances in 
the knowledge of pathogenesis, in the identification of novel targets, in improved 
outcome measures, and in identification and validation of biomarkers may lead to 
effective strategies for AD prevention.
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